March 2026 Transaction Update The Transaction utilizes a UK process (UK RP) that allows us to… Exchange debt for equity and other consideration (i) with our various creditors Allows us to continue to run the Company without interruption during this process i. Consideration for creditors includes a combination of new debt, preferred and common equity. UK Restructuring Plan Transaction Update 2 UK RP Transaction Update We have reached an agreement with our creditors to exchange debt for our equity (1) The pla ...

Core Insights - Aptiv PLC reported better-than-expected fourth-quarter earnings, with revenue of $5.153 billion, up from $4.907 billion a year earlier, reflecting a 3% increase on an adjusted basis [1][2] - The company experienced growth of 8% in North America and 12% in South America, while facing declines of 1% in Europe and Asia [1] - Fourth-quarter adjusted EPS was $1.86, beating the analyst estimate of $1.85, while revenue exceeded the estimate of $5.105 billion [2] Financial Guidance - For Q1 2026, Aptiv guided net sales between $4.950 billion and $5.150 billion, with U.S. GAAP diluted EPS forecasted at $0.60 to $0.80, and adjusted EPS at $1.55 to $1.75 [3] - For the full year 2026, the company forecasts net sales of $21.120 billion to $21.820 billion, with U.S. GAAP diluted EPS of $5.75 to $6.35, and adjusted EPS of $8.15 to $8.75 [3] Strategic Developments - The company is working towards the spin-off of its EDS business as Versigent, aiming to create two independent companies with increased flexibility for market opportunities and capital allocation strategies [4] - Following the earnings announcement, Aptiv shares gained 2.6%, trading at $80.08 [4] Analyst Ratings - Wells Fargo analyst maintained an Overweight rating on Aptiv and raised the price target from $99 to $102 [5] - Oppenheimer analyst maintained an Outperform rating and raised the price target from $102 to $106 [5]

Core Viewpoint - Siemens Energy's CEO acknowledged the legitimacy of activist investor Ananym Capital's call for a spin-off of its unprofitable wind turbine division, emphasizing the need for the business to be stabilized and turned around first [1] Group 1 - The CEO's statement reflects a recognition of shareholder concerns regarding the performance of the wind turbine division [1] - The company is currently focused on stabilizing the wind turbine business before considering any structural changes such as a spin-off [1]

Core Insights - Johnson & Johnson plans to spin out its orthopedics business, creating a standalone company named DePuy Synthes, to enhance focus on higher-growth and higher-margin markets [2][4] - The spinout is expected to occur within the next 18 to 24 months and aims to position J&J as a leader in healthcare innovation [2][5] - The orthopedics unit generated approximately $9.2 billion in sales for fiscal year 2024, with a slight year-over-year revenue decline of 0.3% in the first nine months of 2025 [4] Business Strategy - The decision to separate the orthopedics unit is part of a broader strategy to shift J&J's medtech portfolio towards areas with greater unmet needs, such as cardiovascular and robotic surgery [2][5] - The CEO emphasized that the spinout would create the largest and most comprehensive orthopedics company in the medical device sector, benefiting from a more focused strategy [3][5] - J&J's medtech unit will consist of its cardiovascular, surgery, and vision businesses post-spinout [5] Market Context - The planned spinout follows a trend in the medical device industry, as evidenced by Medtronic's recent announcement to separate its diabetes business into a standalone entity [6]